Architect or Destroyer: The Diversity of Glucocorticoid Receptor Signaling Pathways in the Brain
- 1Medical Research and Education Institute, Lomonosov Moscow State University, 27/10, Lomonosovsky Ave., 119192 Moscow, Russia
Abstract
Glucocorticoids (GCs), acting through the glucocorticoid (GR) and mineralocorticoid (MR) receptors, are essential for brain development, stress adaptation, and metabolic homeostasis, yet their signaling exhibits context-dependent diversity yielding either beneficial or detrimental outcomes. This review synthesizes current knowledge on the multifaceted mechanisms through which GR integrates hormonal, metabolic, and stress signals to modulate transcriptional programs in the brain. We highlight three key levels of GR regulatory complexity: the diversity of DNA GR-binding motifs, GR-mediated epigenetic remodeling, and rapid non-genomic cascades. Clinical and experimental data reveal that while physiological GC levels are critical for normal maturation and function, excess or chronic exposure, especially during sensitive developmental windows, can disrupt neurogenesis, synaptogenesis, and myelination, predisposing individuals to cognitive, affective, and neurodegenerative disorders. We discuss promising therapeutic strategies based on selective modulation of MR/GR balance, interference with specific co-regulatory complexes, and targeted manipulation of DNMT/TET/HDAC cascades. Unlike most existing reviews—which address either (a) the MR–GR interaction as a whole receptor system, (b) non-genomic effects in isolation from genomic ones, or (c) the clinical manifestations of stress-associated disorders without an in-depth mechanistic analysis of GR targets—our manuscript attempts to integrate these three levels of GR regulation into a unified hierarchical system (binding motifs → epigenetic remodeling → the conditional nature of the boundary between genomic and non-genomic GR effects). We aim to explicitly demonstrate how these levels jointly determine cell-specific outcomes, rather than describing them in parallel as independent mechanisms. However, critical gaps remain in understanding the precise assembly of GR-co-regulator complexes in defined neuronal and glial populations, as well as the feasibility of selectively engaging beneficial GR signaling branches without systemic suppression of the hypothalamic–pituitary–adrenal axis. Addressing these questions is essential for developing next-generation therapies that harness GR’s architectural potential while avoiding its adverse or unwanted consequences.
Related
- Glucocorticoid receptor regulates osteoblast differentiation in association with Map7d2 and Erk2 signaling
- Glucocorticoid Receptor Interacts with the TRKB Transmembrane Domain and modulates TRKB Dimerization and Neuronal Plasticity
- Astrocyte glucocorticoid receptor signalling restricts neuronal plasticity
- The glucocorticoid receptor–autophagy axis in inflammation, immunoregulation, and cancer: a bidirectional regulatory network with therapeutic potential
- Glucocorticoid receptor modulation as a host-directed strategy for inflammatory priming across chronic disease states
BibTeX
@article{shkarina2026architect,
title = {{Architect or Destroyer: The Diversity of Glucocorticoid Receptor Signaling Pathways in the Brain}},
author = {Liliia Shkarina and Raushana Khaybullina and Alexandra Primak and Kirill Bozov and Stalik Dzhauari and Maxim Karagyaur},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27209027},
url = {https://www.mdpi.com/1422-0067/27/20/9027},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Architect or Destroyer: The Diversity of Glucocorticoid Receptor Signaling Pathways in the Brain
AU - Liliia Shkarina
AU - Raushana Khaybullina
AU - Alexandra Primak
AU - Kirill Bozov
AU - Stalik Dzhauari
AU - Maxim Karagyaur
PY - 2026
DA - 2026/10/12
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27209027
UR - https://www.mdpi.com/1422-0067/27/20/9027
AB - Glucocorticoids (GCs), acting through the glucocorticoid (GR) and mineralocorticoid (MR) receptors, are essential for brain development, stress adaptation, and metabolic homeostasis, yet their signaling exhibits context-dependent diversity yielding either beneficial or detrimental outcomes. This review synthesizes current knowledge on the multifaceted mechanisms through which GR integrates hormonal, metabolic, and stress signals to modulate transcriptional programs in the brain. We highlight three key levels of GR regulatory complexity: the diversity of DNA GR-binding motifs, GR-mediated epigenetic remodeling, and rapid non-genomic cascades. Clinical and experimental data reveal that while physiological GC levels are critical for normal maturation and function, excess or chronic exposure, especially during sensitive developmental windows, can disrupt neurogenesis, synaptogenesis, and myelination, predisposing individuals to cognitive, affective, and neurodegenerative disorders. We discuss promising therapeutic strategies based on selective modulation of MR/GR balance, interference with specific co-regulatory complexes, and targeted manipulation of DNMT/TET/HDAC cascades. Unlike most existing reviews—which address either (a) the MR–GR interaction as a whole receptor system, (b) non-genomic effects in isolation from genomic ones, or (c) the clinical manifestations of stress-associated disorders without an in-depth mechanistic analysis of GR targets—our manuscript attempts to integrate these three levels of GR regulation into a unified hierarchical system (binding motifs → epigenetic remodeling → the conditional nature of the boundary between genomic and non-genomic GR effects). We aim to explicitly demonstrate how these levels jointly determine cell-specific outcomes, rather than describing them in parallel as independent mechanisms. However, critical gaps remain in understanding the precise assembly of GR-co-regulator complexes in defined neuronal and glial populations, as well as the feasibility of selectively engaging beneficial GR signaling branches without systemic suppression of the hypothalamic–pituitary–adrenal axis. Addressing these questions is essential for developing next-generation therapies that harness GR’s architectural potential while avoiding its adverse or unwanted consequences.
SN - 1422-0067
ER -